Alembic Pharmaceuticals Ltd (APLLTD) is currently trading at 797.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alembic Pharmaceuticals is an integrated, research-driven pharmaceutical company focused on generic formulations, specialty therapies, APIs and animal health, with manufacturing and commercial operations spanning India, the US and multiple international markets and a recently launched US branded specialty franchise under Alembic Therapeutics. Q1 FY27 was a broad-based growth quarter: consolidated revenue rose 26% year-on-year to INR2,150 crores, EBITDA grew 21% to INR348 crores with a 16% margin, and PAT increased to INR173 crores, reflecting higher volumes, new US launches, and improved manufacturing utilisation despite continued strategic investments. The US business was the standout, growing 49% YoY in rupee terms driven by volume-led growth, new product launches (seven in Q1), ten approvals and 180-day exclusivity on two Bosutinib strengths; management now expects the US generics business to grow in the mid-to-high teens for FY27. Alembic continues to invest heavily in future growth: R&D spend was INR186 crores (about 9% of revenue) focused on peptide development, exhibit batches and regulatory filings, while the company is scaling the US branded specialty platform (Pivya launched March 2026) with expectation of positive contribution next financial year. Animal Health and ex-US markets delivered strong momentum — Animal Health grew ~24% in Q1 and international markets were healthy — while management reinforced disciplined commercial execution in India and capacity debottlenecking to sustain growth and improve operating leverage.

Over the past 52 weeks, Alembic Pharmaceuticals Ltd has traded between a low of ₹635.30 and a high of ₹998.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alembic Pharmaceuticals Ltd has a market capitalization of approximately 15,629.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alembic Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.67 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 15,629.72 Cr, Alembic Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alembic Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd is 22.67. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations rose 26% YoY to ₹2,149.77 crore, and consolidated net profit increased 12.1% YoY to ₹173.07 crore for the quarter ended June 30, 2026.

The post-results conference call is scheduled for Tuesday, August 4, 2026, at 5:30 PM IST, after the board meeting on the same day.

The post-results conference call is scheduled for Tuesday, August 4, 2026 at 5:30 PM IST, after the board meeting on the same day.

The USFDA completed a cGMP inspection at Alembic’s Karakhadi facility (Feb 9-18, 2026) and issued a Form 483 with two observations.